Skip to main content

Quick Connect Quick Connect

White Paper

Sacubitril/Valsartan (LCZ696) – Bringing yet another advantage through innovative API offerings

Our team of process and analytical experts draw on their integrated understanding in both the development and manufacturing of the API and the formulation. This is of particular importance when it comes to the characterization of a molecular complex which is critical for a successful API and formulation development. This holistic view, also helps to better understand the impact of the formulation process on the molecular integrity and stability of the product. As a result, our development of this supra molecular complex, was able to robustly match the characteristics of the reference listed drug (RLD).

Read our latest whitepaper on this topic by filling the contact form below.

You can also explore our Sacubitril/Valsartan (LCZ696) offering by clicking on the link below:

Please fill the Contact form below in order to view the white paper